ArriVent BioPharma (AVBP) vs Kura Oncology (KURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 17, 2026.
Summary
Kura Oncology (KURA) has outperformed ArriVent BioPharma (AVBP) over the past year, losing 7.7% versus a loss of 15.1%. ArriVent BioPharma is the larger company by market cap ($821.5 million vs $807.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVBP | KURA |
|---|---|---|
| Share price | $16.66 | $9.08 |
| Market cap | $821.47M | $807.76M |
| 1-day change | -0.77% | -6.39% |
| YTD return | -17.20% | -12.61% |
| 1-year return | -15.11% | -7.72% |
| 5-year return | — | -48.29% |
| EPS (TTM) | $-3.62 | $-3.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $67.48M |
| Revenue growth (YoY) | — | +25.24% |
| Net income (latest FY) | $-166.31M | $-278.67M |
| Operating margin | — | -449.94% |
| Net margin | — | -412.95% |
| 52-week high | $35.83 | $13.90 |
| 52-week low | $11.36 | $7.36 |
| Distance from 52-week high | -53.50% | -34.68% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +23.41% | +250.77% |
| Average volume | 1.00M | 1.82M |
| Shares outstanding | 49.31M | 88.96M |
| Employees | 77 | 260 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ArriVent BioPharma
AVBP stock →ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 77 employees
About Kura Oncology
KURA stock →Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
AVBP vs KURA FAQ
Which is bigger, ArriVent BioPharma or Kura Oncology?
ArriVent BioPharma (AVBP) is larger, with a market capitalization of $821.47M compared with $807.76M for Kura Oncology (KURA).
Which stock has performed better over the past year, AVBP or KURA?
KURA returned -7.72% over the past 12 months, compared with -15.11% for AVBP (price return, excluding dividends). Past performance does not predict future results.
Are ArriVent BioPharma and Kura Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.